NewsRoom Articles - Page 2 of 238

ThursdayMay 28, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma is advancing a clinical-stage multiple sclerosis program targeting demyelination, a differentiated approach compared to many existing therapies focused primarily on immune modulation. The company maintains royalty participation and equity ownership exposure to unbuzzd(TM) while preserving pharmaceutical and medical-use rights to related formulations. Lucid-MS has completed Phase 1 safety studies and advanced into the IND submission stage ahead of a planned Phase 2 clinical trial in multiple sclerosis. Quantum BioPharma’s portfolio spans both therapeutic drug development and consumer-focused wellness products, creating multiple potential operational and…

WednesdayMay 27, 2026 12:00 pm

Earth Science Tech Inc. (ETST) Drives Shareholder Value Through Multi-Sector Diversification and Ongoing Buybacks

Earth Science Tech has positioned itself as a diversified healthcare holding company focused on pharmaceutical compounding, telemedicine, healthcare services, and strict capital allocation. The company recently completed a vertically integrated telehealth and pharmacy ecosystem through the launch of MyOnlineConsultation.com, with telemedicine capabilities supporting patient acquisition, while pharmacy operations drive high-margin recurring prescription-based revenue streams. Above all, Earth Science Tech emphasizes balance-sheet strength and capital discipline through ongoing share repurchase initiatives designed to reduce dilution and support shareholder value. The growing company operates multiple subsidiaries spanning compounding pharmacies, telehealth platforms, clinics, healthcare support services, real estate and cash management. Over the…

WednesdayMay 27, 2026 9:45 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Is ‘One to Watch’

GelrinC(R) is positioned as a potential first-in-class, off-the-shelf solution for knee cartilage repair in the U.S., offering a single-step procedure that simplifies treatment and integrates into standard surgical workflows. Clinical data show ~100% greater pain improvement versus microfracture, with durable outcomes and MRI-confirmed regeneration of near-native cartilage. A single ~10-minute procedure with ~2-week recovery and lower costs versus cell-based therapies supports strong adoption across surgeons, payers, and patients. The product targets an estimated ~$3 billion U.S. market with ~470,000 annual cases and no comparable ready-to-use competitor. Advancing through a pivotal Phase III trial with CE Mark approval in Europe, the…

TuesdayMay 26, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Advances CNS Drug Delivery Strategy as BBB Breakthroughs Drive New Biotech Market Opportunity

OTLC completed a $12.5M monetization of its N2B CNS delivery system with Lunai Bioworks, targeting Alzheimer’s and biodefense applications The deal grants field-specific IP rights while preserving Oncotelic’s development in other CNS indications The move aligns with the rising industry focus on blood-brain barrier (“BBB”) bypass technologies and platform-based CNS drug delivery Oncotelic Therapeutics (OTCQB: OTLC) is advancing its position in one of biotechnology’s most persistent and commercially significant challenges: drug delivery to the central nervous system (“CNS”). As the industry increasingly recognizes the blood-brain barrier (“BBB”) as a primary constraint in neurological drug development, companies developing delivery-focused platforms are…

FridayMay 22, 2026 10:00 am

Study Finds That Errors in Brain Cell Division Could Trigger Cancer

Researchers at the University of Virginia have conducted a study that offers new insights into what happens when there are errors in the process of brain cells dividing to form new cells as the brain is growing. Their findings could open the door to treating cancer and many developmental disorders of the brain. For a while, scientists have known that abscission, the process through which the bridge between dividing cells is cut, is involved in neurodevelopmental disorders and cancer. The genes regulating abscission are particularly of concern since they control that division process. The University of Virginia team sought to understand what happens when abscission doesn’t happen…

FridayMay 22, 2026 9:45 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair

Approximately 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, yet no approved off-the-shelf solution capable of regenerating hyaline-like cartilage is currently available in the U.S. market Regentis' GelrinC(R) is a cell-free hydrogel implant designed to repair focal knee cartilage defects in a single approximately 10-minute procedure, with CE Mark approval in Europe and a pivotal U.S. FDA trial now more than 50% enrolled A newly patented solvent-free manufacturing process that increases GelrinC(R) production yield by 400% signals Regentis' preparation for commercial scale-up as clinical and regulatory milestones approach Knee cartilage damage remains one of the most…

ThursdayMay 21, 2026 11:15 am

Oncotelic Therapeutics Inc. (OTLC) Proving Small Biotech Can Out-Innovate Big Pharma with 28 Million Reasons Why

The global AI in drug-discovery market was valued at approximately $3.25 billion in 2026 and is projected to reach more than $10 billion by 2031. Oncotelic's central technology, the PDAOAI platform, was designed from the outset to be something more than a research accelerator for internal programs. The most significant development to date came when Oncotelic announced the successful integration of approximately 28 million scientific abstracts, into its PDAOAI platform. Artificial intelligence is no longer a buzzword in the life sciences; rather, it is rapidly becoming the defining infrastructure layer of modern drug development. The companies that control the most intelligent platforms…

ThursdayMay 21, 2026 10:00 am

Scientists Inch Closer to Developing a Lung Cancer Blood Test

Unlike prostate, colon and breast cancers, the screening for lung cancer hasn’t been very successful. This is largely because screening focuses on just one risk factor, smoking history, yet many people who develop the disease don’t have a history of smoking. Now, scientists have made progress in developing a blood test that could help in flagging individuals who are at a higher risk of developing lung cancer. A new study whose findings appeared in JAMA suggests that it could be possible to scan blood samples and identify signs of possible lung cancer. The test focused on 13 biomarkers and the researchers found that it could identify 85% of lung cancer cases among smokers. Current screening methods using CT…

ThursdayMay 21, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Expands AI Voice Platform with Fatigue Detection Module

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics is expanding its AI voice analytics platform to include fatigue detection alongside drug and alcohol impairment screening. MindBio filed a patent application covering detection of neurologically active substances and fatigue through voice analysis. Fatigue prediction module will be added to Edge AI Intoxication Detection Kiosks targeted at industrial workplaces. Management says commercial testing of kiosk hardware and software remains on track for late Q2 2026. The company is positioning its technology as a non-invasive alternative to breath, saliva, blood and laboratory-based testing systems, with…

TuesdayMay 19, 2026 10:00 am

Health Care Affordability Crisis Creates Momentum for Single-Payer System in Massachusetts

As the cost of health care skyrockets across the U.S., residents in many states are mobilizing to push their state governments to enact laws creating a single-payer system as a way of making health care more affordable for everyone. This movement is especially gaining traction in Massachusetts. Auden Cote-L’Heureux, an economics expert at the University of Massachusetts (UMass) at Amherst, says Americans pay a lot more for health care yet health outcomes are worse in the U.S. when compared to the stats from comparable countries. For example, he says Americans paid an average of almost $15,000 in 2024 for each…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’

Earth Science Tech Inc. (ETST) Drives Shareholder Value Through Multi-Sector Diversification and Ongoing Buybacks

Regentis Biomaterials Ltd. (NYSE American: RGNT) Is ‘One to Watch’

Oncotelic Therapeutics Inc. (OTLC) Advances CNS Drug Delivery Strategy as BBB Breakthroughs Drive New Biotech Market Opportunity

Study Finds That Errors in Brain Cell Division Could Trigger Cancer

Regentis Biomaterials Ltd. (NYSE American: RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair

Oncotelic Therapeutics Inc. (OTLC) Proving Small Biotech Can Out-Innovate Big Pharma with 28 Million Reasons Why

Scientists Inch Closer to Developing a Lung Cancer Blood Test

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Expands AI Voice Platform with Fatigue Detection Module

Health Care Affordability Crisis Creates Momentum for Single-Payer System in Massachusetts

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search